Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quetiapine fumarate, quantity: 57.575 mg (equivalent: quetiapine, qty 50 mg) - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; povidone; purified talc; lactose monohydrate; magnesium stearate; sodium chloride; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - quetiapine modified release tablets are indicated for:,bipolar disorder,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia,?treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy.,major depressive disorder,?treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies.,generalised anxiety disorder,?treatment of generalised anxiety disorder (gad).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 114.3 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atomoxetine hydrochloride, quantity: 91.44 mg (equivalent: atomoxetine, qty 91.44 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atomoxetine hydrochloride, quantity: 68.58 mg (equivalent: atomoxetine, qty 68.58 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atomoxetine hydrochloride, quantity: 45.72 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atomoxetine hydrochloride, quantity: 28.58 mg (equivalent: atomoxetine, qty 25 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; maize starch; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atomoxetine hydrochloride, quantity: 20.57 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: dimeticone 350; sodium starch glycollate type a; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch; pregelatinised maize starch; titanium dioxide; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.